PDCD1 and melanoma: Although immune checkpoint blockade against PD‐1 or PD‐L1 has had high success in numerous solid cancers, including melanoma, renal cell cancer, and NSCLC, their effect in B‐NHL has been mostly restricted to DLBCL and FL with a modest effect [105].